Quanterix

The lab will provide researchers in the Asia-Pacific region with access to Quanterix's Simoa technology and biomarker testing, development, and validation services.

The company said it has priced a public offering of 3,571,428 shares of its common stock at $70.00 per share.

The company also projected full year 2020 revenue of between $84 million and 86 million and said that its instrument install base grew 34 percent over the year.

For the three months ended Sept. 30, the Billerica, Massachusetts-based company posted Q3 revenues of $31.4 million, up from $14.9 million in Q3 2019.

The awards will support clinical validation, manufacturing, and scale up for SARS-CoV-2 viral antigen and molecular detection.

News items for the week of August 10, 2020.

The company said that it has priced a public offering of 2,651,108 shares of its common stock at $32 per share.

The company posted Q2 revenues of $13.1 million, down from $13.5 million in Q2 2019 but above the consensus Wall Street estimate of $11.8 million.